1. Introduction {#s0005}
===============

The Pouch of Douglas (POD), also known as rectouterine pouch and posterior cul-de-sac, is bordered anteriorly by the posterior uterus and posteriorly by the rectosigmoid colon. It is lined by peritoneum which originates from remnants of the Mullerian system which does not participate in organogenesis ([@bb0050]). Due to the common embryology, benign and malignant lesions which mimic the Mullerian system can develop in the POD. A second mechanism for primary POD malignancies is the malignant transformation of endometriosis.

Primary POD malignancies are rare. In an extensive search of current English literature, 31 cases of primary POD malignancies were identified, with the first case reported by [@bb0010]. Mullerian types POD tumors reported include adenosarcoma, carcinosarcoma, clear cell adenocarcinoma and papillary serous carcinoma. Other tumor types reported include placenta site trophoblastic tumor, malignant mesothelioma and extragastrointestinal stromal tumor.

This paper reports 11 cases of primary POD malignancies in a single center, the largest series so far in literature.

2. Materials and methods {#s0010}
========================

Patients diagnosed with primary POD malignancies from January 2006 to December 2016 were identified from the cancer registry in KK Women\'s and Children\'s Hospital (KKWCH) Gynecology department. The final diagnoses were based on intraoperative and histological findings after our multidisciplinary meeting. Intraoperatively, these tumors may be described to be located in the POD, rectovaginal pouch or rectovaginal septum. Data collected included age at diagnosis, presenting complaints, imaging studies, surgical findings, histology, treatment and progress.

3. Results {#s0015}
==========

There were 11 patients identified with primary POD malignancies in the past ten years ([Table 1](#t0005){ref-type="table"}). All of them were diagnosed in KKWCH and had subsequent treatment within the same center except for one who returned to Malaysia after primary surgery. The youngest was 24 years old at diagnosis while the oldest was 74 years old. The presenting symptoms were varied, including abdominal pain and distension, abnormal uterine bleeding, lump at introitus and reduced stool caliber. The majority were thought to have either uterine or ovarian pathology except for four whose pre-operative scans suggested POD malignancies. Imaging modalities used included pelvic ultrasounds, magnetic resonance imaging (MRI) and computed tomography (CT). On histology post-operatively, there were seven adenocarcinomas (one unspecified, two endometrioid, one adenosquamous and three serous), two carcinosarcoma, one adenosarcoma and one perivascular epitheliod tumor (PEComa). Three patients had synchronous endometrial and POD malignancies. Four out of the seven adenocarcinomas and the adenosarcoma were found to have concurrent endometriosis as seen on histology. Five patients have died of the disease. The remaining patients have had no relapses so far at this point of writing and were disease free between 6 months to 10 years.Table 1Cases of primary POD malignancies diagnosed in KKWCH from January 2006 to December 2016.Table 1Case no.Age[a](#tf0005){ref-type="table-fn"}Presenting complaintImagingPreoperative diagnosis[b](#tf0010){ref-type="table-fn"}Intraoperative findingHistology of POD tumorConcurrent endometriosisPostoperative diagnosisTreatmentProgress151 yearsAbdominal painUS pelvis: 6 cm posterior cervical mass extending to lower uterine segment\
MRI: 8 cm mass involving left posterolateral wall of uterusLeiomyosarcomaPOD filled with tumorEndometrioid adenocarcinoma grade 2YesStage II POD endometrioid cancerSurgery (suboptimal debulking[c](#tf0015){ref-type="table-fn"}), adjuvant paclitaxel and carboplatinDisease free 1 year 5 months248 yearsProlonged menstrual bleedingUS pelvis: 0.7 cm posterior uterine wall fibroidEndometrial complex hyperplasia, unable to exclude transformation to adenocarcinoma2 cm rectovaginal septum tumorEndometrioid adenocarcinoma grade 1YesSynchronous Stage IA endometrial endometrioid adenocarcinoma and Stage II POD cancerSurgery, adjuvant paclitaxel and carboplatin, radiotherapyDisease free 5 years339 yearsDysmenorrhea and menorrhagiaUS pelvis: 2 cm posterior uterine wall fibroidEndometrial endometrioid adenocarcinoma8 cm rectovaginal septum tumorEndometrioid adenosquamous carcinoma grade 2NoSynchronous Stage IA endometrial endometrioid adenocarcinoma and Stage II POD adenosquamous tumorSurgeryUnknown443 yearsIntermenstrual and postcoital bleedingUS pelvis:\
Cannot exclude underlying adenomyosis of posterior uterine wallEndometrial endometrioid adenocarcinoma grade 2POD obliterated, friable tissue at rectovaginal septumAdenocarcinoma Grade 2YesSynchronous endometrium endometrioid adenocarcinoma with POD tumorSurgery, adjuvant paclitaxel and carboplatin, radiotherapyDisease free 10 years552 yearsReduced stool caliberUS pelvis: 8.1 cm complex mass posterior to cervix\
CTAP: 8.4 cm pelvic mass arising from upper vagina/cervixPOD mass5 cm rectovaginal tumorPapillary serous adenocarcinoma grade 3NoStage IIC POD papillary serous adenocarcinomaNeoadjuvant paclitaxel and carboplatin, interval surgery, adjuvant paclitaxel and carboplatin, radiotherapy, vault brachytherapyDWD 4 years 10 months641 yearsAbdominal discomfort and massUS pelvis: 6 cm right pedunculated fibroid\
10 cm complex left ovarian cystFibroid\
Left ovarian cystCaseating rumor in POD\
11 cm left ovarian tumorPapillary serous carcinoma Grade 3\
Hemorrhagic ovarian cystNoStage II POD papillary serous carcinomaSurgery, adjuvant carboplatin and paclitaxelDisease free 8 years 2 months749 yearsIrregular menstrual cycles, foul smelling vaginal dischargeMRI pelvis: 8.5 cm ill-defined mass in POD involving both ovariesMetastatic ovarian carcinoma versus sarcomatous change of tissues in POD1 cm rectovaginal septum tumorSerous adenocarcinoma grade 2YesStage IIIC grade 2 POD tumorNeoadjuvant carboplatin, interval debulking surgery, adjuvant carboplatinDWD 3 years 7 months864 yearsAbdominal bloating, loss of appetite Previous THBSO for POD endometrioma at 63 yearsUS pelvis: 4.8 cm complex lesion in POD\
MRI pelvis: 5.4 cm complex mass in PODPOD tumor recurrenceLarge pelvic tumorAdenosarcoma with sarcomatous overgrowthYesPOD adenosarcomaSurgery (suboptimal debulking), adjuvant doxorubicinDWD 5 months964 yearsAbdominal bloating\
Previous breast cancer at 51 years old in remissionMRI pelvis: 7 cm POD massPOD tumor5 cm rectovaginal tumorCarcinosarcomaNoStage III POD carcinosarcomaNeoadjuvant carboplatin and paclitaxel, interval surgeryDWD 3 years 7 months1074 yearsLump at introitusMRI pelvis: 7.5 cm mass in PODSynchronous endometrial and ovarian cancer versus metastatic endometrial cancer8.5 cm POD tumorCarcinosarcomaNoStage IIIC carcinosarcomaSurgery (suboptimal debulking), adjuvant paclitaxel and carboplatinDisease free 6 months1124 yearsAbdominal massCTAP: 22.2 cm abdominopelvic massAbdominopelvic mass20 cm tumor arising from PODMalignant PEComa--Stage IIIA POD PEComaSurgery, adjuvant doxorubicin and ifosfamideDWD 1 year[^1][^2][^3][^4]

4. Discussion {#s0020}
=============

The POD is named after the Scottish anatomist, James Douglas. It is the most dependent portion of a woman\'s pelvis and thus a common location for fluid, abscesses and drop metastases. Primary malignancy can also occur in the POD, albeit rare, with only 31 cases reported in English literature so far. Evaluation of a POD begins with a thorough physical examination and is aided by a variety of imaging modalities. Pelvic ultrasound is usually the imaging modality of choice to evaluate pelvic masses as it is relatively inexpensive and does not require use of a contrast agent. MRI can be valuable if the lesions need further characterization or if better delineation of soft tissues is needed to plan for surgery. However, due to rarity of primary POD malignancies and the varied presenting symptoms, POD lesions can be mistaken as lesions from ovarian or uterine origin or metastases. Case 10 ([Table 1](#t0005){ref-type="table"}) presented with a lump in the introitus and a routine pre-vaginal hysterectomy endometrial biopsy incidentally showed endometrial cancer. The differential diagnosis based on the endometrial biopsy and the MRI finding of a POD mass was either synchronous endometrial and ovarian cancer or metastatic endometrial cancer. Cases 2 to 4 presented with abnormal uterine bleeding and pre-operative diagnoses based on endometrial biopsies were endometrial hyperplasia or endometrial cancer. Their pelvic ultrasounds did not show any lesions in the POD suspicious for malignancy. POD tumors, which have invaded into the uterine serosa, may also appear as leiomyosarcoma or fibroids on scans, as seen in cases 1 and 6.

The majority of the cases in this case series were Mullerian type malignancies with five out of the ten cases having concomitant endometriosis. In a meta-analysis of studies comparing endometriotic associated ovarian cancers (EAOC) to non-endometriosis associated ovarian cancers (NEAOC) ([@bb0040]), EAOC was associated with early stage and low grade disease. However, there were no significant differences in progression-free survival and overall survival between EAOC and NEAOC after adjusting for histology, FIGO stage and other confounding factors ([@bb0040]). Among the five patients with concomitant endometriosis, four of them had low to moderate grade POD adenocarcinomas and were disease free between 17 months to five years. For the patients with Mullerian type POD malignancies without concurrent endometriosis, one had moderate grade adenosquamous carcinoma, two had high grade carcinomas and two had carcinosarcomas. Two were dead with disease at 42 months and 58 months and the remaining two were disease free at 6 months and 8 years.

Mullerian adenosarcomas are mixed neoplasms composing of benign epithelial and malignant stromal (sarcomatous) components, typically arising from the uterus. While adenosarcomas are generally of low malignant potential and have good prognosis, a subgroup which exhibits sarcomatous overgrowth have higher rates of recurrence and much poorer prognosis ([@bb0005]). The site of origin of adenosarcomas also affects their clinical behavior. Extragenital adenosarcomas are found to have higher rates of recurrence and mortality rates than uterine adenosarcomas ([@bb0025]). There are five cases of POD adenosarcomas reported in literature ([@bb0025], [@bb0035]). Due to the scarcity of cases, there is no consensus on optimal treatment for extragenital adenosarcomas. All five cases had primary surgery and three of them had adjuvant chemotherapy. Chemotherapy regimens included platinum based agents, ifosfamide and doxorubicin. [@bb0025] reported complete response of recurrent POD adenosarcoma with sarcomatous overgrowth with doxorubicin. In this present study, case 8 who had adenosarcoma with sarcomatous overgrowth was dead with disease at five months. She had suboptimal debulking surgery and adjuvant doxorubicin. In the case reported by Huang et al., the patient had optimal debulking surgery and also had complete resection of the recurrence. Surgery is the mainstay of treatment for extragenital adenosarcomas and optimal debulking should be achieved whenever possible.

Extrauterine carcinosarcomas are very rare, with ten cases of primary POD carcinosarcomas reported in literature ([@bb0030], [@bb0045], [@bb0055], [@bb0065], [@bb0075]). Carcinosarcomas are very aggressive tumors with poor prognosis. Due to its rarity, the treatment is often based on prior experience with uterine sarcomas. All the ten patients with POD carcinosarcomas reported in literature had primary surgeries, four with adjuvant chemotherapy, one with adjuvant radiotherapy and one with both adjuvant chemotherapy and radiotherapy. Chemotherapy regimens used included cisplatin with either ifosfamide or adriamycin or ifosfamide as single agent. Six patients were dead with disease within 12 months. The longest disease free interval was 60 months in a case reported by [@bb0045], in which the patient underwent optimal cytoreductive surgery, chemotherapy with ifosfamide and cisplatin and radiotherapy. In this current study, two patients had carcinosarcoma of the POD. One had neoadjuvant paclitaxel and cisplatin with optimal interval cytoreductive surgery. Unfortunately her disease was progressive and she died after 43 months. The other patient had suboptimal cytoreductive surgery and adjuvant chemotherapy with paclitaxel and cisplatin. She is disease free at six months but longer follow-up is needed.

PEComas refer to a family of mesenchymal tumors composed of perivascular epitheliod cells ([@bb0015]) and can range from benign to malignant ([@bb0020]). PEComas have been identified in multiple anatomical sites for example liver, lung and uterus among others ([@bb0060]). Malignant PEComas are aggressive tumors with lack of effective therapies and most affected patients have poor prognosis ([@bb0070]). This current study reports the first case of POD PEComa. She was treated with surgery and six cycles of doxorubicin and ifosfamide. Her disease progressed despite treatment and died at one year post surgery.

5. Conclusion {#s0025}
=============

Primary POD malignancies are rare and patients are often diagnosed with ovarian or uterine pathologies. Similar to endometriotic associated ovarian cancers, the POD malignancies with concomitant endometriosis tend to be of low to moderate grade. However more cases will need to be analyzed to verify the association. Treatment of primary POD malignancies includes primary surgery with adjuvant therapy depending on histology. With the rarer histology types, adjuvant treatment is typically based on reported cases or prior experience with the same histology types in more common sites of origin.

[^1]: US: ultrasound; MRI: magnetic resonance imaging; CTAP: computed tomography of abdomen and pelvis; DWD: dead with disease.

[^2]: Age at diagnosis.

[^3]: Based on clinical findings, imaging studies and/or biopsies.

[^4]: Optimal debulking defined as \< 1 cm of residual disease.
